Following the recent occurrence of International NASH Day and the International Liver Congress meeting in Vienna, NASHNET is releasing an innovative white paper, titled: Biomarkers for Diagnosing and Staging Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Current Perspectives and Potential Future Applications.
Key highlights from the white paper include:
Personal, societal, and economic burden associated with having NAFLD and its subtypes.
Identification of biomarkers and guideline-directed use of biomarkers for diagnosing and staging NAFLD and NASH.
Challenges to successful implementation of NITs within clinical care pathways.
NAFLD and NASH (the more severe form of the disease) have been identified as pressing global health concerns, impacting a 30% and 5% of the world’s population, respectively. With a growing body of scientific literature supporting the use of non-invasive diagnostics to identify and stage NAFLD, NASHNET engaged a multidisciplinary NASH Biomarkers Task Force to generate consensus and define the role non-invasive diagnostics play in optimal NAFLD and NASH care pathways.
This white paper was made possible with financial support from Novo Nordisk, Inc.